Bench-to-bedside translation of magnetic nanoparticles

被引：61
|
作者：
Singh, Dhirender [1 ,2 ]
McMillan, JoEllyn M. [2 ]
Kabanov, Alexander V. [3 ]
Sokolsky-Papkov, Marina [3 ]
Gendelman, Howard E. [1 ,2 ]
机构：
[1] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA
[2] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA
[3] Univ N Carolina, UNC Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC USA
来源：
NANOMEDICINE | 2014年 / 9卷 / 04期
关键词：
biocompatibility; drug targeting; magnetic hyperthermia; MRI; nanoparticle; targeted drug and gene delivery; tissue engineering; IRON-OXIDE NANOPARTICLES; BLOOD-BRAIN-BARRIER; DRUG-DELIVERY; GENE DELIVERY; IN-VIVO; TARGETED DELIVERY; REENGINEERING BIOPHARMACEUTICALS; BIOMEDICAL APPLICATIONS; PLGA NANOPARTICLES; OXIDATIVE STRESS;
D O I：
10.2217/nnm.14.5
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Magnetic nanoparticles (MNPs) are a new and promising addition to the spectrum of biomedicines. Their promise revolves around the broad versatility and biocompatibility of the MNPs and their unique physicochemical properties. Guided by applied external magnetic fields, MNPs represent a cutting-edge tool designed to improve diagnosis and therapy of a broad range of inflammatory, infectious, genetic and degenerative diseases. Magnetic hyperthermia, targeted drug and gene delivery, cell tracking, protein bioseparation and tissue engineering are but a few applications being developed for MNPs. MNPs toxicities linked to shape, size and surface chemistry are real and must be addressed before clinical use is realized. This article presents both the promise and perils of this new nanotechnology, with an eye towards opportunity in translational medical science.
引用
收藏
页码：501 / 516
页数：16
相关论文
共 50 条
  • [21] Bench-to-bedside review: Lactate and the lung
    Iscra, F
    Gullo, A
    Biolo, G
    CRITICAL CARE, 2002, 6 (04): : 327 - 329
  • [22] Bench-to-bedside solution to funding problems
    Bakhoum, Samuel F.
    NATURE, 2006, 443 (7111) : 506 - 506
  • [23] Bench-to-bedside review: Lactate and the kidney
    Bellomo, R
    CRITICAL CARE, 2002, 6 (04): : 322 - 326
  • [24] Bench-to-Bedside Theranostics in Nuclear Medicine
    Jokar, Narges
    Assadi, Majid
    Yordanova, Anna
    Ahmadzadehfar, Hojjat
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (31) : 3804 - 3811
  • [25] Bench-to-bedside review: Metabolism and nutrition
    Casaer, Michael P.
    Mesotten, Dieter
    Schetz, Miet R. C.
    CRITICAL CARE, 2008, 12 (04):
  • [26] Targeted Radiotherapeutics from 'Bench-to-Bedside'
    Muller, Cristina
    Behe, Martin
    Geistlich, Susanne
    van der Meulen, Nicholas P.
    Schibli, Roger
    CHIMIA, 2020, 74 (12) : 939 - 945
  • [27] Bench-to-bedside review: Cytopathic hypoxia
    Mitchell P Fink
    Critical Care, 6
  • [28] Bench-to-bedside review: Carbon dioxide
    Curley, Gerard
    Laffey, John G.
    Kavanagh, Brian P.
    CRITICAL CARE, 2010, 14 (02):
  • [29] Bench-to-bedside solution to funding problems
    Samuel F. Bakhoum
    Nature, 2006, 443 : 506 - 506
  • [30] Nutrition in Sepsis: A Bench-to-Bedside Review
    De Waele, Elisabeth
    Malbrain, Manu L. N. G.
    Spapen, Herbert
    NUTRIENTS, 2020, 12 (02)
12345